The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer

Gynecologic Oncology

Volumn 117, Issue 1, 2010, Pages 109-116

  Steffensen, K D ^a,b   Waldstrom M ^a   Brandslund, Ivan ^a   Jakobsen, A ^a,b  

^a LILLEBAELT HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Ovarian cancer; PFS; Serum VEGF; VEGF polymorphism

Indexed keywords

CARBOPLATIN; GENOMIC DNA; PACLITAXEL; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DNA EXTRACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIAL OVARIAN CANCER; FEMALE; GENOTYPE; HAPLOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; OVARY CANCER; PATIENT REFERRAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DISEASE-FREE SURVIVAL; FEMALE; GENOTYPE; HAPLOTYPES; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; POLYMORPHISM, SINGLE NUCLEOTIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77949304088     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.11.011     Document Type: Article

References (39)

1. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat. Med. 9 6 (2003) 669-676
2. Jain R.K. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin. Oncol. 29 6 Suppl 16 (2002) 3-9
3. Giatromanolaki A., Sivridis E., and Koukourakis M.I. Angiogenesis in colorectal cancer: prognostic and therapeutic implications. Am. J. Clin. Oncol. 29 4 (2006) 408-417
4. Gasparini G. Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist 5 Suppl 1 (2000) 37-44
5. Delongchamps N.B., Peyromaure M., and nh-Xuan A.T. Role of vascular endothelial growth factor in prostate cancer. Urology 68 2 (2006) 244-248
6. Bamberger E.S., and Perrett C.W. Angiogenesis in epithelian ovarian cancer. Mol. Pathol. 55 6 (2002) 348-359
7. Rudlowski C., Pickart A.K., Fuhljahn C., Friepoertner T., Schlehe B., Biesterfeld S., et al. Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up. Int. J. Gynecol. Cancer 16 Suppl 1 (2006) 183-189
8. Yamamoto S., Konishi I., Mandai M., Kuroda H., Komatsu T., Nanbu K., et al. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br. J. Cancer 76 9 (1997) 1221-1227
9. Watson C.J., Webb N.J., Bottomley M.J., and Brenchley P.E. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 12 8 (2000) 1232-1235
10. Brogan I.J., Khan N., Isaac K., Hutchinson J.A., Pravica V., and Hutchinson I.V. Novel polymorphisms in the promoter and 5' UTR regions of the human vascular endothelial growth factor gene. Hum. Immunol. 60 12 (1999) 1245-1249
11. Renner W., Kotschan S., Hoffmann C., Obermayer-Pietsch B., and Pilger E. A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J. Vasc. Res. 37 6 (2000) 443-448
12. Stevens A., Soden J., Brenchley P.E., Ralph S., and Ray D.W. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res. 63 4 (2003) 812-816
13. Li L., Wang L., Zhang W., Tang B., Zhang J., Song H., et al. Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer. Anticancer Res. 24 3b (2004) 1973-1979
14. Alvarez S.A., Sayer R., Snyder S.A., Broadwater G., Rodriguez G.C., Berchuck A., et al. The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer. Gynecol. Oncol. 94 1 (2004) 74-79
15. Cooper B.C., Ritchie J.M., Broghammer C.L., Coffin J., Sorosky J.I., Buller R.E., et al. Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin. Cancer Res. 8 10 (2002) 3193-3197
16. Hefler L.A., Zeillinger R., Grimm C., Sood A.K., Cheng W.F., Gadducci A., et al. Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Gynecol. Oncol. 103 2 (2006) 512-517
17. Gadducci A., Ferdeghini M., Fanucchi A., Annicchiarico C., Ciampi B., Prontera C., et al. Serum preoperative vascular endothelial growth factor (VEGF) in epithelial ovarian cancer: relationship with prognostic variables and clinical outcome. Anticancer Res. 19 2B (1999) 1401-1405
18. Steffensen K.D., Waldstrom M., Jeppesen U., Knudsen H.J., Brandslund I., and Jakobsen A. Preoperative serum levels of epidermal growth factor receptor, HER2, and vascular endothelial growth factor in malignant and benign ovarian tumors. Clinical Ovarian Cancer 1 2 (2008) 127-134
19. Hefler L.A., Mustea A., Konsgen D., Concin N., Tanner B., Strick R., et al. Vascular endothelial growth factor gene polymorphisms are associated with prognosis in ovarian cancer. Clin. Cancer Res. 13 3 (2007) 898-901
20. Polterauer S., Grimm C., Mustea A., Concin N., Tanner B., Thiel F., et al. Vascular endothelial growth factor gene polymorphisms in ovarian cancer. Gynecol. Oncol. 105 2 (2007) 385-389
21. Smerdel M.P., Waldstrom M., Brandslund I., Steffensen K.D., Andersen R.F., and Jakobsen A. Prognostic importance of vascular endothelial growth factor-A expression and vascular endothelial growth factor polymorphisms in epithelial ovarian cancer. Int. J. Gynecol. Cancer 19 4 (2009) 578-584
22. Rustin G.J. Use of CA-125 to assess response to new agents in ovarian cancer trials. J. Clin. Oncol. 21 10 Suppl (2003) 187-193
23. Rustin G.J., Quinn M., Thigpen T., du B.A., Pujade-Lauraine E., Jakobsen A., et al. Re: new guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J. Natl. Cancer Inst. 96 6 (2004) 487-488
24. Stephens M., Smith N.J., and Donnelly P. A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 68 4 (2001) 978-989
25. Stephens M., and Scheet P. Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am. J. Hum. Genet. 76 3 (2005) 449-462
26. Harlozinska A., Sedlaczek P., Kulpa J., Grybos M., Wojcik E., Van Dalen A., et al. Vascular endothelial growth factor (VEGF) concentration in sera and tumor effusions from patients with ovarian carcinoma. Anticancer Res. 24 2C (2004) 1149-1157
27. Tempfer C., Obermair A., Hefler L., Haeusler G., Gitsch G., and Kainz C. Vascular endothelial growth factor serum concentrations in ovarian cancer. Obstet. Gynecol. 92 3 (1998) 360-363
28. Chen C.A., Cheng W.F., Lee C.N., Chen T.M., Kung C.C., Hsieh F.J., et al. Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival. Gynecol. Oncol. 74 2 (1999) 235-240
29. Vincenzi B., Santini D., Russo A., Gavasci M., Battistoni F., Dicuonzo G., et al. Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan. Pharmacogenomics 8 4 (2007) 319-327
30. Smerdel MP, Steffensen KD, Waldstrom M, Brandslund I, Jakobsen A. The predictive value of serum VEGF/VEGFR1-2 in bevacizumab treated ovarian cancer patients. Oral abstract presentation. ESGO meeting, Belgrade. Abtract # 391. 13-10-2009. Ref Type: Abstract
31. Axel D.I., Kunert W., Goggelmann C., Oberhoff M., Herdeg C., Kuttner A., et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 96 2 (1997) 636-645
32. Lau D.H., Xue L., Young L.J., Burke P.A., and Cheung A.T. Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Cancer Biother. Radiopharm. 14 1 (1999) 31-36
33. Albertsson P., Lennernas B., and Norrby K. Chemotherapy and antiangiogenesis: drug-specific effects on microvessel sprouting. APMIS 111 11 (2003) 995-1003
34. Krippl P., Langsenlehner U., Renner W., Yazdani-Biuki B., Wolf G., Wascher T.C., et al. A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int. J. Cancer 106 4 (2003) 468-471
35. Koukourakis M.I., Papazoglou D., Giatromanolaki A., Bougioukas G., Maltezos E., and Sivridis E. VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer 46 3 (2004) 293-298
36. Masago K., Fujita S., Kim Y.H., Hatachi Y., Fukuhara A., Nagai H., et al. Effect of vascular endothelial growth factor polymorphisms on survival in advanced-stage non-small-cell lung cancer. Cancer Sci. (2009)
37. Bradbury P.A., Zhai R., Ma C., Xu W., Hopkins J., Kulke M.J., et al. Vascular endothelial growth factor polymorphisms and esophageal cancer prognosis. Clin. Cancer Res. 15 14 (2009) 4680-4685
38. Dassoulas K., Gazouli M., Rizos S., Theodoropoulos G., Christoni Z., Nikiteas N., et al. Common polymorphisms in the vascular endothelial growth factor gene and colorectal cancer development, prognosis, and survival. Mol. Carcinog. 48 6 (2009) 563-569
39. Schultheis A.M., Lurje G., Rhodes K.E., Zhang W., Yang D., Garcia A.A., et al. Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin. Cancer Res. 14 22 (2008) 7554-7563